Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2015

01-02-2015 | Original Article

Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation

Authors: Danilo D. Trevisan, Juliana B. Silva, Henrique C. Oliveira, Silvia R. Secoli, Maria Helena M. Lima

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2015

Login to get access

Abstract

Patients undergoing hematopoietic stem cell transplantation (HSCT) are at risk of developing potential drug–drug interactions (PDDIs). The aim of this study was to assess the prevalence of PDDIs that occur in HSCT patients on the day of hematopoietic stem cell infusion. We performed a cross-sectional study based on the evaluation of prescriptions to HSCT patients on the day of infusion (day 0). The PDDIs were analyzed using the DRUG-REAX® system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact. Forty patients undergoing HSCT were included in this study; 33 patients (82.5 %) were exposed to at least one major and one contraindicated PDDI in a concomitant manner. All patients exposed to PDDIs had an increased risk of cardiotoxicity. Most cases of PDDIs were classified as being of major severity (80.9 %), with time of onset not specified (61.9 %), and with good or excellent scientific evidence (52.4 %). HSCT patients have a high prevalence of clinically significant PDDIs. The management of PDDIs requires an approach that includes biochemical tests, installation of cardiac monitors, periodic electrocardiograms, implementation of electronic prescriptions with a PDDI alert system, and availability of the PDDI databases.
Literature
1.
Guastaldi RBF, Secoli SR (2011) Drug interactions of anti-microbial agents used in hematopoietic stem cell transplantation. Rev Lat Am Enfermagem 19:960–967PubMedCrossRef
2.
Glotzbecker B, Duncan C, Alyea E, Campbell B, Soiffer R (2012) Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 18:989–1006PubMedCrossRef
3.
Guastaldi RBF, Reis AMM, Figueras A, Secoli SR (2011) Prevalence of potential drug–drug interactions in bone marrow transplant patients. Int J Clin Pharm 33:1002–1009PubMedCrossRef
4.
Antin JH, Raley DY (2013) Manual of stem cell and bone marrow transplantation. Cambrigde University Press, New YorkCrossRef
5.
Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592–600PubMedCrossRef
6.
7.
Tatro DS (2011) Drug interactions facts. Wolters Kluwer Health/Facts & Comparisons, St Louis
8.
Bachmann KA (2003) Drug interactions handbook. Lexi-Comp, Hudson
9.
van Leeuwen RWF, Brundel DHS, Neef C et al (2013) Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108:1071–1078PubMedCentralPubMedCrossRef
10.
Lu C, Liao M, Cohen L, Xia CQ (2010) Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug–drug interactions. Curr Drug Discov Technol 7:199–222PubMed
11.
Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250:327–341PubMedCrossRef
12.
Gholaminezhad S, Hadjibabaie M, Gholami K et al (2014) Pattern and associated factors of potential drug–drug interactions in both pre- and early post-hematopoietic stem cell transplantation stages at a referral center in the middle east. Ann Hematol 93:1913–1922PubMedCrossRef
13.
Egger SS, Meier S, Leu C et al (2010) Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 45:1197–1203PubMedCrossRef
14.
Jaklič A, Collins CJ, Mrhar A et al (2013) High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther 51:711–717PubMedCentralPubMed
15.
16.
17.
18.
19.
20.
Ruping MJ, Vehreschild JJ, Cornely OA (2008) Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68:1941–1962PubMedCrossRef
21.
22.
McCoy D, Depestel DD, Carver PL (2009) Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. Pharmacotherapy 29:1306–1325PubMedCrossRef
23.
Nivoix Y, Ubeaud-Sequier G, Engel P, Leveˆque D, Herbrecht R (2009) Drug–drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 10:395–409PubMedCrossRef
24.
Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24:545–553PubMedCrossRef
25.
Lopes LA, Veroneze I, Burgardt CI, Niebel Stier CJ (2014) Prophylaxis with levofloxacin: impact on bacterial susceptibility and epidemiology in a hematopoietic stem cell transplant unit. Rev Bras Hematol Hemoter 36:35–42PubMedCentralCrossRef
26.
Hadjibabaie M, Badri S, Ataei S et al (2013) Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol 71:1619–1627PubMedCrossRef
27.
28.
Freedman SB, Uleryk E, Rumantir M, Finkelstein Y (2014) Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 64:19–25PubMedCrossRef
29.
Koeller JM, Aapro MS, Gralla RJ et al (2002) Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10:519–522PubMedCrossRef
30.
Robinson RF, Nahata MC, Olshefski RS (2000) Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 34:1406–1409PubMedCrossRef
31.
Blower PR (2002) 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 8:405–414PubMedCrossRef
32.
33.
Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332–341PubMedCrossRef
34.
Hazin R, Abuzetun JY, Suker M, Porter J (2008) Rhabdomyolysis induced by simvastatin–fluconazole combination. J Natl Med Assoc 100:444–446PubMed
35.
Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR (2003) Simvastatin–fluconazole causing rhabdomyolysis. Ann Pharmacother 37:1032–1035PubMedCrossRef
36.
Jamal SM, Eisenberg MJ, Christopoulos S (2004) Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme a reductase inhibitors. Am Heart J 147:956–965PubMedCrossRef
37.
Kashani A, Phillips CO, Foody JM et al (2006) Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114:2788–2797PubMedCrossRef
38.
Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010) Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33:171–187PubMedCrossRef
39.
Scripture CD, Sparreboom A, Figg WD (2005) Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 6:780–789PubMedCrossRef
40.
Evans WE, McLeod HL (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538–549PubMedCrossRef
41.
42.
Peterson JF, Kuperman GJ, Shek C, Bates DW (2001) Physician responses to life-threatening drug–drug interaction alerts. J Gen Intern Med 16(Suppl 1):212
43.
Abookire SA, Teich JM, Sandige H, et al (2000) Improving allergy alerting in a computerized physician order entry system. In: Proceedings of the AMIA symposium, 2–6
44.
Paterno MD, Maviglia SM, Gorman PN et al (2009) Tiering drug–drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc 16:40–46PubMedCentralPubMedCrossRef
Metadata
Title
Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation
Authors
Danilo D. Trevisan
Juliana B. Silva
Henrique C. Oliveira
Silvia R. Secoli
Maria Helena M. Lima
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2657-8

Other articles of this Issue 2/2015

Cancer Chemotherapy and Pharmacology 2/2015 Go to the issue

Original Article

Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor

Original Article

Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer

Original Article

Oxymatrine targets EGFRp-Tyr845 and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells

Original Article

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

Original Article

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

Original Article

A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits